论文部分内容阅读
经过全世界有关专家的努力,急性白血病的疗效已取得明显的进展。其中以药物治疗的新药开发和方案的更新,以及骨髓移植最为明显。一、药物治疗:急性非淋巴细胞白血病(ANLL)的诱导缓解药物中以阿糖胞苷(CA)(7日)与柔红霉素(DNR)(3日)合用为当今公认标准的7日方案。在大系列的病例报导中其完全缓解率(CR)达75％,疗效优于5日方案,亦不亚于10日方案。增加6-TG、五杂氮胞嘧啶或表足叶素(VP—16)后亦不能增加CR。北京
After the efforts of relevant experts all over the world, the curative effect of acute leukemia has made obvious progress. Among them, drug-treated new drug development and program updates, as well as bone marrow transplantation most obvious. First, the drug treatment: Acute non-lymphocytic leukemia (ANLL) induced remission drugs with cytarabine (CA) (7th) and daunorubicin (DNR) (3rd) combined for today’s standard 7 Program. In a series of case reports, its complete response rate (CR) was 75%, which was superior to the 5-day regimen and less than the 10-day regimen. Increased 6-TG, pentaazo-cytosine or epidermaldehyde (VP-16) also can not increase CR. Beijing